MyoKardia Shares Skyrocket On Promising Phase II Data In HCM

Biotech hopes to accelerate clinical development plans for mavacamten after study meets several endpoints in obstructive hypertrophic cardiomyopathy, an unmet medical need.

Anatomy of Human Heart

It was only 10 patients but the top-line data MyoKardia Inc. unveiled Aug. 7 for its Phase II cardiomyopathy candidate mavacamten had a big impact on the biotech's stock. The company's share price soared 83% on the day and market analysts suggested there could be an opportunity for accelerated clinical development and potential breakthrough therapy designations.

MyoKardia is partnered on the drug with Sanofi, one of its initial investors via the French pharma's Sunrise open innovation initiative. Sanofi paid $45m up front ($10m an equity...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D